Memorandum
- From
- Connor Quincy via fox - Health
- Date
- Filed
- News·5 min to read
- Re
Experimental drug combo shrinks pancreatic tumors in most patients in early trial
ReExperimental drug combo shrinks pancreatic tumors in most patients in early trial
An experimental daily pill paired with standard chemotherapy shrank tumors or halted their growth in most patients with advanced pancreatic cancer in early clinical trial results presented in Barcelona.
An experimental daily pill combined with standard chemotherapy shrank tumors or stopped their growth in most patients with advanced pancreatic cancer, according to early clinical trial results presented Friday at a major international cancer conference. The findings were shared at the EORTC-NCI-AACR Symposium in Barcelona and suggest a new approach for a disease that is among the hardest cancers to treat.
The study, a phase 1/2 trial, tested a daily oral medication called daraxonrasib alongside two standard intravenous chemotherapy drugs, gemcitabine and nab-paclitaxel. The trial enrolled 61 patients whose pancreatic cancer had already spread to other organs and who had not yet received treatment for their advanced disease. Every participant received the experimental combination.
Tumors shrank in 60.7% of cases, and in 8.2% of patients they disappeared entirely on scans. Overall, the combination stopped tumor growth in 90.2% of participants. Patients went a median of 12.8 months before their cancer worsened, almost double the timeframe typically seen with standard chemotherapy alone, and 76.6% were still alive at the one-year mark. The researchers tracked patients for a median follow-up of 18 months.
Pancreatic cancer is notoriously difficult to treat because more than half of patients are diagnosed after the disease has already spread, according to research cited in the study coverage. In major clinical trials for metastatic pancreatic cancer, chemotherapy alone shrinks tumors in about 23% to 42% of patients, but the disease typically begins growing again after five to six months, and most patients survive between 8 and 11 months. National Cancer Institute data show that only about 3% of patients with distant-stage disease live five years past diagnosis.
The approach targets a genetic driver of the disease. More than 90% of pancreatic cancers are fueled by a faulty gene called RAS, which allows tumors to keep growing. Daraxonrasib is designed to switch off that growth signal, something scientists long believed could not be addressed with medication. Study lead Dr. Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center in New York, said in a press release that the team is seeing not only substantial tumor shrinkage, including complete responses, but also durable disease control, with median progression-free survival exceeding one year.
Dr. Elena Garralda, chair of the symposium and co-director of the clinical research program at the Vall d'Hebron Institute of Oncology in Spain, who was not involved in the research, said the results indicate that RAS-targeted drugs can be combined with existing treatments at the start of care to potentially achieve longer-lasting benefits.
Side effects included rash, diarrhea, fatigue and low blood cell counts linked to chemotherapy, most of which were manageable with standard care. Only 5% of patients stopped treatment because of side effects tied to daraxonrasib.
The researchers stressed the study's limitations. Because it was an early-phase, single-group study, there was no comparison group receiving standard chemotherapy alone. Doctors therefore cannot yet confirm how much better the new regimen performs or whether it definitively extends overall survival. The findings also apply only to metastatic pancreatic cancer, even though RAS mutations drive several other cancers, including certain lung, colorectal and gynecological cancers. Separate studies would be needed to test the combination in those diseases.
The trial was funded by Revolution Medicines, the California-based developer of daraxonrasib. To determine whether these early findings translate into a durable survival benefit, researchers have launched a larger, randomized Phase 3 trial called RASolute-303. It directly compares daraxonrasib, both alone and combined with chemotherapy, against standard chemotherapy alone.
32
Source: New drug combo shrinks tumors in most patients facing aggressive cancer type
